hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06285201 id: TJ202001BE104 briefTitle: Study of Felzartamab in Healthy Adult Subjects overallStatus: RECRUITING date: 2024-03-27 date: 2024-12-31 date: 2024-12-31 date: 2024-02-29 date: 2024-04-15 name: TJ Biopharma Co., Ltd. class: INDUSTRY briefSummary: A Phase 1 Clinical Study to Evaluate the Pharmacokinetic Comparability, Safety, Tolerability, and Immunogenicity of Felzartamab for Injection Pre- and Post-changes of Process in Healthy Male Adult Subjects in China (Randomized, Double-blind, Single-dose, Two-formulation, Two-sequence, Two-period Crossover Design) conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: HEALTH_SERVICES_RESEARCH masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: T name: R measure: Primary PK Endpoint sex: MALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: The First Hospital of Jilin University status: RECRUITING city: Jilin state: Changchun country: China name: Xiaojiao Li, Doctor role: CONTACT phone: +8613514314089 email: xingxingsuo123456@126.com lat: 43.85083 lon: 126.56028 hasResults: False
nctId: NCT06285188 id: APHP221174 id: 2023-A01398-37 type: REGISTRY domain: ID-RCB briefTitle: Immunomonitoring of Mold Invasive Infections acronym: IMMUNOFIL overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-12 date: 2026-03 date: 2024-02-29 date: 2024-02-29 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy. conditions: Invasive Fungal Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED measure: Immune checkpoint expression on T cells measure: Aspergillus/Mucorales FLUOROSPOT measure: T cell proliferation measure: Immune checkpoint expression on monocytes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Necker Enfants Malades city: Paris zip: 75015 country: France name: Alexandra SERRIS, MD role: CONTACT phone: +33 6 68 80 24 92 email: alexandra.serris@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06285175 id: APP-22-04497 briefTitle: REINVENT: A Brain and Muscle Computer Interface for Stroke acronym: REINVENT overallStatus: COMPLETED date: 2021-06-01 date: 2023-12-15 date: 2024-02-15 date: 2024-02-29 date: 2024-02-29 name: University of Southern California class: OTHER briefSummary: Stroke is a leading cause of adult disability in the United States. High doses of repeated task-specific practice have shown promising results in restoring upper limb function in chronic stroke (\>6 months after onset). However, it is currently challenging to provide such doses in standard clinical practice. At-home telerehabilitation services supervised by a clinician are a potential solution to provide higher-dose interventions. However, telerehabilitation systems developed for repeated task-specific practice typically require a minimum level of active movement. Therefore, severely impaired people necessitate alternative therapeutic approaches. Measurement and feedback of electrical muscle activity via electromyography (EMG) have been previously implemented in the presence of minimal or no volitional movement to improve motor performance in people with stroke. Specifically, muscle neurofeedback training to reduce unintended co-contractions of the impaired hand may be a targeted intervention to improve motor control in severely impaired populations. In this study, we examine the effects of a low-cost, portable, and modular EMG biofeedback system (Tele-REINVENT) for supervised and unsupervised upper limb telerehabilitation after stroke during a 6-week home-based training program that reinforces activity of the wrist extensor muscles while avoiding coactivation of flexor muscles via computer games. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 14 type: ACTUAL name: Tele-REINVENT measure: Fugl Meyer Assessment - Upper Extremity measure: Maximum EMG activity measure: Corticomuscular coherence sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Southern California city: Los Angeles state: California zip: 90033 country: United States lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06285162 id: 69HCL23_1372 id: 2024-A00294-43 type: OTHER domain: ID-RCB briefTitle: Analgesia Nociception Index to Explore Autonomic Nervous System in Patients With Continuous Renal Replacement Therapy acronym: UFANI overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-07 date: 2025-07 date: 2024-02-29 date: 2024-02-29 name: Hospices Civils de Lyon class: OTHER briefSummary: The Analgesia Nociception Index (ANI) reflects the balance between sympathetic and parasympathetic tone. It is based on a specific interpretation of the R-R interval variation. During fluid removal by net ultrafiltration in patients with fluid overload and continuous renal replacement therapy, some data suggest that haemodynamic variation could be induced by the autonomic nervous system. The study aims to investigate ANI variations in this context and their association with the haemodynamic variations observed. conditions: Critically Ill conditions: Renal Replacement Therapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: Percentage of changes in ANI. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Département d'anesthésie-réanimation Hôpital cardiologique Louis Pradel city: Bron zip: 69500 country: France name: Martin RUSTE, MD role: CONTACT phone: +33472118956 phoneExt: +33 email: martin.ruste@chu-lyon.fr name: Martin RUSTE, MD role: PRINCIPAL_INVESTIGATOR name: Matthias JACQUET-LAGREZE, MD role: SUB_INVESTIGATOR lat: 45.73333 lon: 4.91667 hasResults: False
nctId: NCT06285149 id: AKLD-22 briefTitle: Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-01 date: 2025-06-01 date: 2024-02-29 date: 2024-02-29 name: Henan Cancer Hospital class: OTHER_GOV briefSummary: Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1. It is used for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse standard treatment and have not previously received systemic therapy. According to numerous studies, in tumor cells, Icaritin can downregulate the expression of TNF-α, IL-6, PD-L1 and exert anti-tumor effects. At the same time, it regulates the tumor immune microenvironment by reducing the secretion of TNFa and IL-6 as well as inhibiting PD-L1 expression through decreasing MDSC cell proportion. Importantly, Icaritin has excellent safety profile and greatly ensure patients' quality of life clinically. Rare grade 3-4 TRAEs were observed in clinical trials which is uncommon among existing standard drugs. Good safety is a prerequisite for combination therapy; therefore, further exploration of optimal drug combinations is worth considering. Thus, TACE+Icaritin may potentially optimize treatment strategies for patients with poor liver function reserve. conditions: HCC studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Icaritin measure: ORR measure: PFS measure: Overall survival，OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285136 id: SHEN-PJ-KE-2024-15 briefTitle: Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2026-03-01 date: 2024-02-29 date: 2024-02-29 name: The Second Affiliated Hospital of Kunming Medical University class: OTHER name: Institute of hematology hospital,Chinese Academy of Medical Sciences name: Handan Central Hospital name: Taian City Central Hospital name: Tianjin People's Hospital name: Guizhou Provincial People's Hospital name: Central South University name: Western Theater General Hospital name: First Affiliated Hospital of Guangxi Medical University name: Chengdu Jingdongfang Hospital briefSummary: This study proposes to conduct a prospective, multicenter, single-arm study to explore the efficacy and safety of venetoclax in combination with high-dose decitabine (DEC3-VEN) in new diagnosed adult patients with AML, and to provide evidence for the optimal selection of clinical treatment regimens, which is planned to be conducted in 10 research centers across the country. conditions: Acute Myeloid Leukemia, Adult studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: DEC3-VEN measure: ORR measure: Overall survival (OS) sex: ALL minimumAge: 16 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Kunming Medical University. city: Kunming state: Yunnan country: China lat: 25.03889 lon: 102.71833 hasResults: False
nctId: NCT06285123 id: HUM00248235 and HUM00248331 id: 1U01FD007803-01 type: FDA link: https://reporter.nih.gov/quickSearch/1U01FD007803-01 briefTitle: Implementing the COMFORT Guidelines for Postpartum Pain Management overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-26 date: 2025-07 date: 2026-04 date: 2024-02-29 date: 2024-02-29 name: University of Michigan class: OTHER name: Food and Drug Administration (FDA) briefSummary: A new national clinical practice guideline (CPG) for pain management after childbirth aims to mitigate peripartum opioid-related risks without compromising or exacerbating existing inequities in pain management in the United States. Standard dissemination approaches are often insufficient to change clinical practice-more active implementation efforts are generally required. Replicating Effective Programs (REP) is a theory-driven implementation intervention that is publicly available and highly scalable, but REP alone may be insufficient for effectively embedding the CPG across all maternity sites. For sites needing more support, REP can be augmented with facilitation (e.g., individualized consultation with site champions to overcome local barriers to CPG adoption, "Enhanced-REP" \[E-REP\]). Because E-REP is more expensive and difficult to scale than REP, it is essential to identify those settings where REP alone is effective versus those where REP may need augmentation, but this has not been evaluated in maternity contexts. Our objective is to determine the effect of a new postpartum pain management CPG, as implemented by REP and E-REP, on postpartum opioid prescribing (primary outcome: rate and amount of opioid prescribed within three days of childbirth), overall, by hospital, and among key subgroups.
This is a non-responder randomized trial within the Obstetrics Initiative (OBI), a perinatal collaborative quality initiative funded by Blue Cross Blue Shield of Michigan that includes 68 member hospitals serving more than 120,000 postpartum people over an approximately 15-month study time period. Hospitals not initially responding to REP (defined by performance below the top 15th percentile of all OBI hospitals for a) inpatient order for opioid-sparing postpartum pain management, \[e.g., scheduled acetaminophen and ibuprofen\], or b) amount of opioid prescribed at discharge, or c) provision of non-medication pain management interventions) will be allocated, via block randomization, to either continue REP vs. augment REP with facilitation (E-REP).
The primary analysis will evaluate the rate of postpartum opioid-sparing prescribing metrics at the time of discharge (primary outcome) and opioid prescription refills and high-risk prescribing (secondary outcomes) before and after CPG implementation with REP, using interrupted time series analyses. Inequities in outcomes by patient, procedure, prescriber, and hospital factors will be evaluated. Exploratory analyses will examine temporal trends in patient-reported outcomes. The effects of continued REP vs. E-REP among non-responder sites will also be examined. Finally, implementation outcomes will be characterized using clinician and patient surveys and qualitative methods. conditions: Postpartum Pain conditions: Opioid Stewardship conditions: Maternity Care conditions: Obstetric Care studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 68 type: ESTIMATED name: REP name: Facillitation measure: Postpartum opioid prescribing - Rate measure: Postpartum opioid prescribing - Amount measure: Refill opioid prescribing measure: High-risk opioid prescribing measure: Patient-reported outcomes measure: Implementation outcomes - reach measure: Implementation outcomes - adoption measure: Implementation outcomes - feasibility measure: Implementation outcomes - acceptability measure: Implementation outcomes - appropriateness measure: Implementation outcomes - fidelity measure: Implementation outcomes - potential mechanisms of implementation measure: Implementation outcomes - costs of delivering implementation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan city: Ann Arbor state: Michigan zip: 48109 country: United States lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06285110 id: DTG Resist briefTitle: HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen acronym: DTG-Resist overallStatus: RECRUITING date: 2022-06-13 date: 2025-08-31 date: 2025-08-31 date: 2024-02-29 date: 2024-02-29 name: University of Bern class: OTHER name: University of Zurich name: ETH Zurich name: University of KwaZulu name: University of Bristol briefSummary: This is a prospective observational study enrolling People Living with HIV (PLHIV) who are on a Dolutegravir-based AntiRetroviral Treatment (ART) regimen and experiencing virologic failure. Virologic failure is defined as two consecutive viral load measurements of \>1000 copies/mL of blood. The main aim of the study is to identify the drug-resistance mutations in the viral genome that are associated with this failure.
nctId: NCT06285084 id: VALETUDO Trial (L4195) briefTitle: Deep Learning ECG Evaluation and Clinical Assessment for Competitive Sport Eligibility acronym: VALETUDO overallStatus: RECRUITING date: 2024-02-02 date: 2025-11-02 date: 2027-02-02 date: 2024-02-29 date: 2024-02-29 name: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio class: OTHER briefSummary: The goal of this observationl study is to evaluate the possibility of building a Deep Learning (DL) model capable of analyzing electrocardiographic traces of athletes and providing information in the form of a probability stratification of cardiovascular disease.
Researchers will subsequently enroll a validation cohort of 76 participants. ECG traces will be analyzed to evaluate the accuracy of the model to discriminate participants cleared for sports eligibility versus participants who need further medical tests conditions: Sports Cardiology conditions: Preventive Cardiology conditions: Electrocardiogram conditions: Artificial Intelligence studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 531 type: ESTIMATED measure: DL model accuracy sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Ospedale Galeazzi-Sant'Ambrogio status: RECRUITING city: Milano state: Lombardy zip: 20157 country: Italy name: davide marchetti, MD role: CONTACT phone: +390283506734 email: davide.marchetti@grupposandonato.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06285071 id: NN7415-7557 id: U1111-1274-4740 type: OTHER domain: World Health Organization (WHO) briefTitle: Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors overallStatus: ENROLLING_BY_INVITATION date: 2024-04-30 date: 2030-04-30 date: 2030-04-30 date: 2024-02-29 date: 2024-04-01 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years. conditions: Haemophilia A conditions: Haemophilia B studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 23 type: ESTIMATED name: Concizumab measure: Number of adverse reaction (AR) measure: Number of serious adverse reaction (SAR) measure: Number of serious adverse event (SAE) measure: Number of thromboembolic adverse event (AE) measure: Number of shock/anaphylaxis AE measure: Number of treated spontaneous and traumatic bleeding episodes measure: Number of treated spontaneous and traumatic target joint bleeding episodes measure: Number of all treatment requiring bleeding episode sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Novo Nordisk Investigational Site city: Toshima state: Tokyo country: Japan hasResults: False
nctId: NCT06285058 id: LUNAI briefTitle: Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-12 date: 2026-03 date: 2024-02-29 date: 2024-03-13 name: Wuhan Union Hospital, China class: OTHER briefSummary: This study presents the development and validation of an artificial intelligence (AI) prediction system that utilizes pre-neoadjuvant immunotherapy plain scans and enhanced multimodal CT scans to extract deep learning features. The aim is to predict the occurrence of pathological complete response in non-small cell lung cancer patients undergoing neoadjuvant immunochemotherapyy. conditions: Deep Learning Model conditions: Pathological Complete Response conditions: Non-small Cell Lung Cancer conditions: Neoadjuvant Chemoimmunotherapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: No interventions measure: the accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of predicting model sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285045 id: 2060302-1703-05 briefTitle: Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression overallStatus: COMPLETED date: 2018-10-01 date: 2019-08-31 date: 2019-08-31 date: 2024-02-29 date: 2024-03-05 name: Guang'anmen Hospital of China Academy of Chinese Medical Sciences class: OTHER briefSummary: To evaluate the efficacy and safety of Roujin Formula in the treatment of fibromyalgia syndrome(FMS)patients with blood deficiency and liver depression through a randomized,single-blind,placebo-parallel controlled exploratory clinical trial study,and to provide reliable clinical evidence for the treatment of fibromyalgia syndrome with Roujin Formula. 48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data. conditions: Fibromyalgia Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 48 type: ACTUAL name: Roujin Formula measure: The change of the revised Fibromyalgia Impact Questionnaire (FIQR) from baseline measure: The change of the Visual Analogue Scale (VAS) for pain from baseline measure: The change of the Pittsburgh Sleep Quality Index(PSQI) from baseline measure: The change of the Beck depression inventory(BDI) from baseline measure: The change of the Short Form-36 Health Status Questionnaire(SF-36) from baseline sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Juan Jiao city: Beijing state: Beijing zip: 100053 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06285032 id: STUDY00017244 id: R34DA058325 type: NIH link: https://reporter.nih.gov/quickSearch/R34DA058325 briefTitle: Decreasing Loneliness to Optimize Pain Care acronym: DLoop overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2026-05 date: 2024-02-29 date: 2024-03-01 name: University of Washington class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: Loneliness, which is the perceived feeling of insufficient personal relationships, is related to higher risk for inappropriate opioid use and opioid use disorders in patients who are taking opioids long-term. The study seeks to pilot test the evidence-based loneliness interventions of psychological therapy and social navigation in patients on chronic opioids treated in primary care practices to determine if reducing loneliness can lower opioid misuse. conditions: Loneliness conditions: Opioid Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 102 type: ESTIMATED name: Cognitive Behavior Therapy (CBT) name: Social Navigation Group name: Controlled Group measure: Opioid Misuse measure: Determine Functional Outcome measure: Loneliness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Washington city: Seattle state: Washington zip: 98105 country: United States lat: 47.60621 lon: -122.33207 hasResults: False